ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
Commissural Misalignment Following Valve-in-Valve Transcatheter Aortic Valve Implantation.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Commissural Misalignment Following Valve-in-Valve Transcatheter Aortic Valve Implantation.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData on commissural misalignment (CMA) during valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for valve failure after surgical aortic valve replacement (SAVR) is scarce.
aimsTo study the impact of CMA on clinical and hemodynamic outcomes following ViV-TAVI for failed SAVR.
methodsData of patients who underwent ViV-TAVI for failed SAVR valves at two institutions (Heart Center Leipzig at Leipzig University, Leipzig, Germany; Cedars-Sinai Smidt Heart Institute, Los Angeles, USA) were retrospectively collected and compared regarding the existence of CMA. Outcomes of interest included Valve Academic Research Consortium (VARC)-3-based clinical endpoints, Computed Tomography-based hypoattenuated leaflet thickening (HALT), hemodynamic outcome, and mid-term all-cause mortality.
resultsOf the 687 patients who underwent ViV-TAVI, post-procedural CT of sufficient quality to measure commissural alignment was available in 180 patients (47.8% females, mean age 78.0 years). Self-expanding TAVI valves were used in 49.2% of the cases. CMA was found in 35 individuals (19.4%) and was associated with reduced VARC-3-based technical success (80% vs. 93%, p = 0.03), driven by increased rates of coronary obstruction (17.1% vs. 5.6%, p = 0.03). The incidence of HALT was 31.7%, without differences in patients with and without CMA. VARC-3-based device success was 62.9%, driven by an incidence of residual mean valve gradient (≥ 20 mmHg) of 35.4%, without differences between groups. Midterm survival after a mean of 747 days was 84.6% and comparable between groups.
conclusionsFor patients undergoing ViV-TAVI for failed SAVR, technical success is reduced for cases of CMA due to higher odds of coronary obstruction, without differences in mid-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.